Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 9

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 9
---
 Japan in September 2024.

<div align='center'>4</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

#### Neuroscience
In Neuroscience, revenue was JPY 456.5 billion (JPY -18.4 billion and -3.9% AER, -9.0% CER).

Sales of VYVANSE/ELVANSE (for ADHD) were JPY 287.6 billion (JPY -25.3 billion and -8.1% AER, -13.5% CER). The decrease was due to the multiple generic entrants in the U.S. starting from August 2023, with the growth of the adult market in Europe and favorable foreign exchange rates partially offsetting the negative impacts.

Sales of TRINTELLIX (for major depressive disorder ("MDD")) were JPY 98.1 billion (JPY +17.9 billion, and +22.3% AER, +16.3% CER). The increase was primarily due to the sales increase in the U.S.

Sales of ADDERALL XR (for ADHD) were JPY 23.9 billion (JPY -11.3 billion and -32.2% AER, -35.7% CER). The decrease was primarily due to an increase in the availability of generic versions of the instant release formulation marketed by competitors in the U.S., which negatively impacted ADDERALL XR.

#### Cost of Sales
Cost of Sales was JPY 1,198.1 billion (JPY +154.0 billion and +14.7% AER, +9.5% CER). The increase was primarily due to revenue growth in our six key business areas with a change in product mix and the depreciation of the Japanese yen as compared to the nine-month period ended December 31, 2023.

Selling, General and Administrative (SG&A) Expenses

SG&A Expenses were JPY 808.9 billion (JPY +40.3 billion and +5.2% AER, +0.3% CER). The increase was mainly due to the depreciation of the Japanese yen.

#### Research and Development (R&D) Expenses
R&D Expenses were JPY 514.2 billion (JPY -19.8 billion and -3.7%